U.S. markets close in 3 hours 19 minutes
  • S&P 500

    4,137.98
    -7.21 (-0.17%)
     
  • Dow 30

    32,801.05
    -2.42 (-0.01%)
     
  • Nasdaq

    12,641.17
    -16.39 (-0.13%)
     
  • Russell 2000

    1,937.47
    +15.64 (+0.81%)
     
  • Crude Oil

    90.43
    +1.42 (+1.60%)
     
  • Gold

    1,804.00
    +12.80 (+0.71%)
     
  • Silver

    20.65
    +0.80 (+4.05%)
     
  • EUR/USD

    1.0202
    +0.0015 (+0.14%)
     
  • 10-Yr Bond

    2.7680
    -0.0720 (-2.54%)
     
  • GBP/USD

    1.2083
    +0.0012 (+0.10%)
     
  • USD/JPY

    134.6040
    -0.3660 (-0.27%)
     
  • BTC-USD

    23,883.47
    +760.98 (+3.29%)
     
  • CMC Crypto 200

    556.33
    +13.46 (+2.48%)
     
  • FTSE 100

    7,482.37
    +42.63 (+0.57%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Looking Into Aerie Pharmaceuticals's Return On Capital Employed

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

During Q4, Aerie Pharmaceuticals's (NASDAQ:AERI) reported sales totaled $24.68 million. Despite a 5.92% in earnings, the company posted a loss of $35.59 million. Aerie Pharmaceuticals collected $20.08 million in revenue during Q3, but reported earnings showed a $33.60 million loss.

What Is Return On Capital Employed?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, Aerie Pharmaceuticals posted an ROCE of -1.49%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

View more earnings on AERI

ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Aerie Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.

In Aerie Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.

Q4 Earnings Insight

Aerie Pharmaceuticals reported Q4 earnings per share at $-0.79/share, which did not meet analyst predictions of $-0.73/share.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.